Skip to main content

MM-398-01-03-04: Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer

Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer | NCT03088813

NCT03088813

Principal Investigator

Sponsor

IPSEN Bioscience, Inc.

Trial Type: Treatment.

A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy. The study will be conducted in two parts: 1. Dose determination of irinotecan liposome injection 2. A randomized, efficacy study of irinotecan liposome injection versus topotecan.

This study is currently enrolling.


Interested in participating?

Fill out the information below and we will reach out to you within two business days with more information on qualifications for this trial and how to participate.